AstraZeneca's Brilinta Fails to Win FDA Approval
AstraZeneca failed to win FDA approval for its heart drug Brilinta, which the company -- facing a severe patent cliff -- has high hopes for. If approved, it could be a multibillion-dollar blockbuster. But the FDA wants to see more analyses of results from a major study. Continue reading AstraZeneca's Brilinta Fails to Win FDA Approval AstraZeneca's Brilinta Fails to Win FDA Approval originally appeared on DailyFinance on Fri, 17 Dec 2010 08:08:00. Filed Under: Company News , Health Care , Pfizer , Bristol-Myers Squibb , Sanofi Aventis , Astrazeneca , Stocks in the News Permalink | Tweet this! | Comments
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here